News of Note—McKesson relaunches pharma services

Microphone
(Pixabay)

Here is some news of note for the week: 

 > McKesson has relaunched its biopharmaceutical services business. Release

> The EMA says it may seek to order fluoroquinolone and quinolone antibiotics off the market following a review of disabling and potentially long-lasting side effects. Announcement

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Vetter is expanding its secondary packaging operations, adding a second building to its Ravensburg site which will be ready in 2020. Release

Read more on

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.